Human polymorphonuclear leukocytes inhibit Aspergiam fumigatus conidial growth by lactoferrin-mediated iron depletion

Journal of Immunology

Volumn 178, Issue 10, 2007, Pages 6367-6373

  Zarember, Kol A ^a   Sugui, Janyce A ^a   Chang, Yun C ^a   Kwon Chung, Kyung J ^a,b   Gallin, John I ^a,b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b MSC 1504 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LACTOFERRIN; REACTIVE OXYGEN METABOLITE;

ARTICLE; ASPERGILLUS FUMIGATUS; FUNGUS GROWTH; HOST RESISTANCE; HUMAN; IN VITRO STUDY; IRON DEPLETION; NEUTROPHIL; PRIORITY JOURNAL; SUPERNATANT;

EID: 34248188692     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.10.6367     Document Type: Article

References (58)

1. Miliner, P. D., S. A. Olenchock, E. Epstein, R. Rylander, J. Haines, J. Walker, B. L. Ooi, E. Horne, and M. Maritato. 1994. Bioaerosols associated with composting facilities. Compost Sci. Util. 2: 6-57.
2. Montoya, J. G., S. V. Chaparro, D. Celis, J. A. Cortes, A. N. Leung, R. C. Robbins, and D. A. Stevens. 2003. Invasive aspergillosis in the setting of cardiac transplantation. Clin. Infect. Dis. 37(Suppl. 3): S281-S292.
3. Morrison, V. A., R. J. Haake, and D. J. Weisdorf. 1994. Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome. Am. J. Med. 96: 497-503.
4. Latge, J. P. 1999. Aspergillus fumigatus and aspergillosis. Clin. Microbiol. Rev. 12: 310-350.
5. Alexander, J., A. P. Limaye, C. W. Ko, M. P. Bronner, and K. V. Kowdley. 2006. Association of hepatic iron overload with invasive fungal infection in liver transplant recipients. Liver Transpl. 12: 1731-1732.
6. Altes, A., A. F. Remacha, P. Sarda, F. J. Sancho, A. Sureda, R. Martino, J. Briones, S. Brunet, C. Canals, and J. Sierra. 2004. Frequent severe liver iron overload after stem cell transplantation and its possible association with invasive aspergillosis. Bone Marrow Transplant. 34: 505-509.
7. Iglesias-Osma, C., L. Gonzalez-Villaron, J. F. San Miguel, M. D. Caballero, L. Vazquez, and S. de Castro. 1995. Iron metabolism and fungal infections in patients with haematological malignancies. J. Clin. Pathol. 48: 223-225.
8. Gallin, J. I., D. W. Alling, H. L. Malech, R. Wesley, D. Koziol, B. Marciano, E. M. Eisenstein, M. L. Turner, E. S. DeCarlo, J. M. Starling, and S. M. Holland. 2003. Itraconazole to prevent fungal infections in chronic granulomatous disease. N. Engl. J. Med. 348: 2416-2422.
9. Lin, S. J., J. Schranz, and S. M. Teutsch. 2001. Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Dis. 32: 358-366.
10. Segal, B. H., T. L. Leto, J. I. Gallin, H. L. Malech, and S. M. Holland. 2000. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine 79: 170-200.
11. Winkelstein, J. A., M. C. Marino, R. B. Johnston, Jr., J. Boyle, J. Curnutte, J. I. Gallin, H. L. Malech, S. M. Holland, H. Ochs, P. Quie, et al. 2000. Chronic granulomatous disease: report on a national registry of 368 patients. Medicine 79: 155-169.
12. Rex, J. H., J. E. Bennett, J. I. Gallin, H. L. Malech, and D. A. Melnick. 1990. Normal and deficient neutrophils can cooperate to damage Aspergillus fumigatus hyphae. J. Infect. Dis. 162: 523-528.
13. Schaffner, A., H. Douglas, and A. Braude. 1982. Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus: observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes. J. Clin. Invest. 69: 617-631.
14. Lehrer, R. I., and R. G. Jan. 1970. Interaction of Aspergillus fumigatus spores with human leukocytes and serum. Infect. Immun. 1: 345-350.
15. Levitz, S. M., and R. D. Diamond. 1985. Mechanisms of resistance of Aspergillus fumigatus conidia to killing by neutrophils in vitro. J. Infect. Dis. 152: 33-42.
16. Bonnett, C. R., E. J. Cornish, A. G. Harmsen, and J. B. Burritt. 2006. Early neutrophil recruitment and aggregation in the murine lung inhibit germination of Aspergillus fumigatus conidia. Infect. Immun. 74: 6514-6516.
17. Bellocchio, S., S. Moretti, K. Perruccio, F. Fallarino, S. Bozza, C. Montagnoli, P. Mosci, G. B. Lipford, L. Pitzurra, and L. Romani. 2004. TLRs govern neutrophil activity in aspergillosis. J. Immunol. 173: 7406-7415.
18. Hohl, T. M., H. L. Van Epps, A. Rivera, L. A. Morgan, P. L. Chen, M. Feldmesser, and E. G. Pamer. 2005. Aspergillus fumigatus triggers inflammatory responses by stage-specific β-glucan display. PLoS Pathog. 1: e30.
19. Mambula, S. S., K. Sau, P. Henneke, D. T. Golenbock, and S. M. Levitz. 2002. Toll-like receptor (TLR) signaling in response to Aspergillus fumigatus. J. Biol Chem. 277: 39320-39326.
20. Steele, C., R. R. Rapaka, A. Metz, S. M. Pop, D. L. Williams, S. Gordon, J. K. Kolls, and G. D. Brown. 2005. The β-glucan receptor dectin-1 recognizes specific morphologies of Aspergillus fumigatus. PLoS Pathog. 1: e42.
21. Knowles, M. R., and R. C. Boucher. 2002. Mucus clearance as a primary innate defense mechanism for mammalian airways. J. Clin. Invest. 109: 571-577.
22. Meshulam, T., S. M. Levitz, L. Christin, and R. D. Diamond. 1995. A simplified new assay for assessment of fungal cell damage with the tetrazolium dye, (2,3)-bis-(2-methoxy-4-nitro-5-sulphenyl)-(2H)-tetrazolium-5-carboxanilide (XTT). J. Infect. Dis. 172: 1153-1156.
23. Balajee, S. A., A. Imhof, J. L. Gribskov, and K. A. Marr. 2005. Determination of antifungal drug susceptibilities of Aspergillus species by a fluorescence-based microplate assay. J. Antimicrob. Chemother. 55: 102-105.
24. Bainton, D. F., and M. G. Farquhar. 1966. Origin of granules in polymorphonuclear leukocytes: two types derived from opposite faces of the Golgi complex in developing granulocytes. J. Cell Biol. 28: 277-301.
25. Wright, D. G., D. A. Bralove, and J. I. Gallin. 1977. The differential mobilization of human neutrophil granules: effects of phorbol myristate acetate and ionophore A23187. Am. J. Pathol. 87: 237-284.
26. Esaguy, N., A. P. Aguas, and M. T. Silva. 1989. High-resolution localization of lactoferrin in human neutrophils: labeling of secondary granules and cell heterogeneity. J. Leukocyte Biol. 46: 51-62.
27. Kirkpatrick, C. H., I. Green, R. R. Rich, and A. L. Schade. 1971. Inhibition of growth of Candida albicans by iron-unsaturated lactoferrin: relation to host-defense mechanisms in chronic mucocutaneous candidiasis. J. Infect. Dis. 124: 539-544.
28. Levitz, S. M., and T. P. Farrell. 1990. Human neutrophil degranulation stimulated by Aspergillus fumigatus. J. Leukocyte Biol. 47: 170-175.
29. Levay, P. F., and M. Viljoen. 1995. Lactoferrin: a general review. Haematologica 80: 252-267.
30. Rado, T. A., J. Bollekens, G. St. Laurent, L. Parker, and E. J. Benz, Jr. 1984. Lactoferrin biosynthesis during granulocytopoiesis. Blood 64: 1103-1109.
31. Brown, R. D., E. Yuen, K. A. Rickard, P. C. Vincent, G. Young, and H. Kronenberg. 1986. Plasma lactoferrin in patients with neutropenia. Blut 52: 289-295.
32. Harle, J. R., C. Figarella, C. Fossat, P. J. Weiller, and M. Mongin. 1984. Plasma lactoferrin and the blood count of polynuclear neutrophils. Pathol. Biol. 32: 239-244.
33. Cole, A. M., P. Dewan, and T. Ganz. 1999. Innate antimicrobial activity of nasal secretions. Infect. Immun. 67: 3267-3275.
34. Thompson, A. B., T. Bohling, F. Payvandi, and S. I. Rennard. 1990. Lower respiratory tract lactoferrin and lysozyme arise primarily in the airways and are elevated in association with chronic bronchitis. J. Lab. Clin. Med. 115: 148-158.
35. Jacquot, J., J. M. Tournier, T. G. Cannona, E. Puchelle, J. P. Chazalette, and P. Sadoul. 1983. Proteins of bronchial secretions in mucoviscidosis: role of infection. Bull. Eur. Physiopathol. Respir. 19: 453-458.
36. Alkawash, M., M. Head, I. Alshami, and J. S. Soothill. 1999. The effect of human lactoferrin on the MICs of doxycycline and rifampicin for Burkholderia cepacia and Pseudomonas aeruginosa strains. J. Antimicrob. Chemother. 44: 385-387.
37. DiMario, F., G. Aragona, N. Dal Bo, L. Cavallaro, V. Marcon, P. Olivieri, E. Benedetti, N. Orzes, R. Marin, G. Tafner, et al. 2006. Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. Aliment. Pharmacol. Ther. 23: 1235-1240.
38. Ward, P. P., M. Mendoza-Meneses, G. A. Cunningham, and O. M. Conneely. 2003. Iron status in mice carrying a targeted disruption of lactoferrin. Mol. Cell. Biol. 23: 178-185.
39. Lekstrom-Himes, J. A., S. E. Dorman, P. Kopar, S. M. Holland, and J. I. Gallin. 1999. Neutrophil-specific granule deficiency results from a novel mutation with loss of function of the transcription factor CCAAT/enhancer binding protein ε. J. Exp. Med. 189: 1847-1852.
40. Breton-Gorius, J., D. Y. Mason, D. Buriot, J. L. Vilde, and C. Griscelli. 1980. Lactoferrin deficiency as a consequence of a lack of specific granules in neutrophils from a patient with recurrent infections: detection by immunoperoxidase staining for lactoferrin and cytochemical electron microscopy. Am. J. Pathol. 99: 413-428.
41. Lomax, K. J., J. I. Gallin, D. Rotrosen, G. D. Raphael, M. A. Kaliner, E. J. Benz, Jr., L. A. Boxer, and H. L. Malech. 1989. Selective defect in myeloid cell lactoferrin gene expression in neutrophil specific granule deficiency. J. Clin. Invest. 83: 514-519.
42. Jordan, W. J., J. Eskdale, G. P. Lennon, R. Pestoff, L. Wu, D. H. Fine, and G. Gallagher. 2005. A non-conservative, coding single-nucleotide polymorphism in the N-terminal region of lactoferrin is associated with aggressive periodontitis in an African-American, but not a Caucasian population. Genes Immun. 6: 632-635.
43. Velliyagounder, K., J. B. Kaplan, D. Furgang, D. Legarda, G. Diamond, R. E. Parkin, and D. H. Fine. 2003. One of two human lactoferrin variants exhibits increased antibacterial and transcriptional activation activities and is associated with localized juvenile periodontitis. Infect. Immun. 71: 6141-6147.
44. Kasahara, Y., K. Iwai, A. Yachie, K. Ohta, A. Konno, H. Seki, T. Miyawaki, and N. Taniguchi. 1997. Involvement of reactive oxygen intermediates in spontaneous and CD95 (Fas/APO-1)-mediated apoptosis of neutrophils. Blood 89: 1748-1753.
45. Pollock, J. D., D. A. Williams, M. A. Gifford, L. L. Li, X. Du, J. Fisherman, S. H. Orkin, C. M. Doerschuk, and M. C. Dinauer. 1995. Mouse model of X-linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production. Nat. Genet. 9: 202-209.
46. phox-/- mice: implications for fungal pathogenicity and host defense in chronic granulomatous disease. J. Clin. Invest. 101: 1843-1850.
47. phox mouse knock-out model of chronic granulomatous disease. J. Exp. Med. 182: 751-758.
48. Hissen, A. H., J. M. Chow, L. J. Pinto, and M. M. Moore. 2004. Survival of Aspergillus fumigatus in serum involves removal of iron from transferrin: the role of siderophores. Infect. Immun. 72: 1402-1408.
49. Hissen, A. H., A. N. Wan, M. L. Warwas, L. J. Pinto, and M. M. Moore. 2005. The Aspergillus fumigatus siderophore biosynthetic gene sidA, encoding L-ornithine N5-oxygenase, is required for virulence. Infect. Immun. 73: 5493-5503.
50. Schrettl, M., E. Bignell, C. Kragl, C. Joechl, T. Rogers, H. N. Arst, Jr., K. Haynes, and H. Haas. 2004. Siderophore biosynthesis but not reductive iron assimilation is essential for Aspergillus fumigatus virulence. J. Exp. Med. 200: 1213-1219.
51. Elin, R. J., S. M. Wolff, and C. A. Finch. 1977. Effect of induced fever on serum iron and ferritin concentrations in man. Blood 49: 147-153.
52. Krause, A., S. Neitz, H. J. Magert, A. Schulz, W. G. Forssmann, P. Schulz-Knappe, and K. Adermann. 2000. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 480: 147-150.
53. Ganz, T. 2003. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102: 783-788.
54. Nemeth, E., E. V. Valore, M. Territo, G. Schiller, A. Lichtenstein, and T. Ganz. 2003. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 101: 2461-2463.
55. Ganz, T., and E. Nemeth. 2006. Iron imports. IV. Hepcidin and regulation of body iron metabolism. Am. J. Physiol. 290: G199-G203.
56. Boelaert, J. R., M. de Locht, J. Van Cutsem, V. Kerrels, B. Cantinieaux, A. Verdonck, H. W. Van Landuyt, and Y. J. Schneider. 1993. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection: in vitro and in vivo animal studies. J. Clin. Invest. 91: 1979-1986.
57. De Locht, M., J. R. Boelaert, and Y. J. Schneider. 1994. Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus. Biochem. Pharmacol. 47: 1843-1850.
58. Yun, C. W., T. Ferea, J. Rashford, O. Ardon, P. O. Brown, D. Botstein, J. Kaplan, and C. C. Philpott. 2000. Desferrioxamine-mediated iron uptake in Saccharomyces cerevisiae: evidence for two pathways of iron uptake. J. Biol. Chem. 275: 10709-10715.